---
layout: default
title: Cetuximab
parent: 僅模型預測 (L5)
nav_order: 99
evidence_level: L5
indication_count: 10
---

# Cetuximab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Cetuximab: From Original Indication Not Reported to Bronchial Adenomas/Carcinoids, Childhood

## One-Sentence Summary

Cetuximab is an anti-EGFR monoclonal antibody (per the model's own annotation); this evidence pack does not record its formally approved original indication or detailed mechanism of action. TxGNN's top-ranked prediction is **Bronchial Adenomas/Carcinoids, Childhood**, but this pairing is supported by **0 clinical trials** and **0 publications** — the pack's own rationale states the score reflects graph-similarity inference only, with no EGFR-driven mechanism demonstrated in this pediatric rare tumor.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not reported in this evidence pack (data gap) |
| Predicted New Indication | Bronchial Adenomas/Carcinoids, Childhood |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L5 |
| Finland Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from DrugBank in this pack (flagged as data gap DG002, High severity). Based on the model's own rationale annotations, cetuximab is known to be an anti-EGFR (epidermal growth factor receptor) monoclonal antibody.

No original indication data is populated in this pack, so the relationship between cetuximab's established use and this predicted indication cannot be assessed here.

Critically, the pack's own repurposing rationale for this top-ranked prediction states plainly that **no EGFR-driven pathology has been reported** for bronchial adenomas/carcinoids in children, and that the high TxGNN score reflects knowledge-graph similarity inference rather than any clinical or mechanistic support. This prediction should therefore be treated as hypothesis-generating only, not as a signal with biological plausibility established.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## Finland Market Information

Cetuximab is not marketed in this jurisdiction per this evidence pack — market status "未上市" (Not Marketed), with 0 total authorizations on record. No license entries are available to tabulate.

## Cytotoxicity

Cetuximab is an antineoplastic agent (anti-EGFR monoclonal antibody, used across this pack's evidence in combination with cytotoxic chemotherapy regimens such as FOLFOX and cisplatin).

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (anti-EGFR monoclonal antibody) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked TxGNN prediction (Bronchial Adenomas/Carcinoids, Childhood) has zero supporting clinical trials or literature, and the model's own mechanistic rationale explicitly disclaims any EGFR-driven biological plausibility for this pairing — the score is a pure graph-embedding artifact.

**To proceed, the following is needed:**
- TFDA package insert data (DG001, Blocking — currently prevents any S1 safety screening)
- DrugBank-sourced mechanism of action and original approved indications (DG002)
- At minimum, preclinical/mechanistic evidence establishing EGFR expression or dependency in pediatric bronchial adenomas/carcinoids before this candidate can move beyond S0

**Note:** Within this same evidence pack, other ranked candidates for cetuximab carry substantially stronger evidence — notably rank 8 "cystic neoplasm" and rank 10 "pre-malignant neoplasm" (both L2, S2, backed by Phase 2/3 trials including a completed n=987 Phase 3 in HPV-associated oropharynx cancer). Those may warrant a separate, dedicated evaluation report rather than further investment in the rank-1 candidate assessed here.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

